Rush to Judgement: Imaginary Worlds and Cost-Outcomes Claims for PCSK9 Inhibitors

INNOVATIONS in pharmacy
doi 10.24926/iip.v8i2.516
Full Text
Abstract

Available in full text

Date
Authors
Publisher

University of Minnesota

Related search

Are PCSK9 Inhibitors Cost Effective?

PharmacoEconomics
Health PolicyPublic HealthOccupational HealthPharmacologyEnvironmental
2018English

Reproductive Cloning: Don't Rush to Judgement

Nature
Multidisciplinary
2003English

PCSK9 Peptide Inhibitors

Science-Business eXchange
2014English

Cost Effectiveness of Proprotein Convertase Subtilisin/ Kexin Type 9 (PCSK9) Inhibitors

Cardiovascular Disorders and Medicine
2019English

PCSK9 Inhibitors: A Technology Worth Paying For?

PharmacoEconomics
Health PolicyPublic HealthOccupational HealthPharmacologyEnvironmental
2015English

Validating Imaginary Worlds? The AdViSHE Assessment Tool

INNOVATIONS in pharmacy
2017English

PCSK9 Inhibitors: When Statins Aren't Enough

Prescriber
Pharmacology
2017English

Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice

Postgraduate Medicine
Medicine
2016English

Imaginary Worlds: The Status of Modeled Quality Adjusted Life Year Claims for New Oral Anticoagulants in Atrial Fibrillation Published Between January 2012 and February 2016

INNOVATIONS in pharmacy
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy